Optomed was founded in Oulu, Finland in 2004 by Seppo Kopsala Optomed’s CEO, with the vision to design and produce a smaller and more affordable fundus camera than traditionally used desktop cameras, which would improve the efficiency of the eye screening of diabetics. In the early years, the operations were focused on research and development with a long-term perspective and sales activities were limited.
At the beginning of the journey, Optomed developed three early product generations. In 2013, Optomed reached a major milestone when, to our knowledge, it launched the world’s first handheld fundus camera meeting the fundus camera standard ISO 10940 resolution requirements, Smartscope PRO. In 2017, Optomed launched its fifth handheld fundus camera generation, Optomed Aurora.
Since the beginning of its operations, Optomed has sold handheld fundus cameras under its own brand and since 2010 under globally leading OEM customers brands. Optomed’s OEM-customers are; Volk Optical Inc., Carl Zeiss Meditec Inc., Haag-Streit Diagnostics and Topcon Medical Systems Inc.
An important step for Optomed was the expansion into the Chinese market in 2014 by establishing a subsidiary focused on marketing, sales and distribution channel management.
Optomed has been recognized as one of the 50 fastest-growing technology companies in Finland through the Deloitte Technology Fast 50 program in 2016 and in 2017. The Financial Times recognized Optomed as one of the 1000 fastest-growing companies in Europe in 2018.
The business took a big step in 2018 when Optomed acquired software company Commit; Oy (presently Optomed Software Oy) which develops and sells software solutions for health care organisations. Through the acquisition, Optomed has evolved from handheld fundus cameras provider into a provider of complete fundus screening solutions and the pioneer of introducing AI-solutions in eye screening.